Litcius/Paper detail

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Hartmut Goldschmidt, Marc‐Andrea Baertsch, Jana Schlenzka, Natália Becker, Christina Habermehl, Thomas Hielscher, Marc‐Steffen Raab, Jens Hillengaß, Sandra Sauer, Carsten Müller‐Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Göerner, Stefan Klein, Martin Schmidt‐Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans Walter Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel

2020Leukemia67 citationsDOI

Topics & Concepts

LenalidomideMedicineMultiple myelomaMelphalanDexamethasoneInternal medicineSalvage therapySurgeryAutologous stem-cell transplantationTransplantationClinical endpointHematopoietic stem cell transplantationOncologyRandomized controlled trialChemotherapyMultiple Myeloma Research and TreatmentsCancer Treatment and PharmacologyCancer therapeutics and mechanisms